体外系统完全恢复先天性不育小鼠的卵子发生
研究在Kitl基因位点突变所致先天性不育的KitlSl-t/KitlSl-t小鼠中,比较腺相关病毒(AAV)载体瞬时表达Kitl或补充重组KITL能否完全恢复生育。两种方法均获得成熟卵母细胞并产出健康可育后代,AAV8-Kitl在1.0×10^11 vg/ml时次级卵泡数最多(每个重建卵巢80个),47只后代基因组未检出AAV DNA。
要点
- AAV8-Kitl以剂量依赖方式促进原始卵泡激活,1.0×10^11 vg/ml时次级卵泡数最多。
- 200 ng/ml重组KITL支持次级卵泡形成,水平与野生型小鼠卵巢相当。
- 无论何种处理方法,超过10%的受精卵发育至足月,47只后代均未检出AAV DNA。
核心结论
- 通过AAV载体瞬时表达Kitl或补充重组KITL,可在KitlSl-t/KitlSl-t先天性不育小鼠中产生成熟卵母细胞并产出健康可育后代。
研究设计与样本
- 研究为小鼠实验:用AAV-mCherry感染野生型小鼠卵巢,在15种血清型中比较表达水平以筛选最佳AAV血清型。
- 在KitlSl-t/KitlSl-t小鼠卵巢中评估AAV-Kitl感染(六种剂量;N=3-5)和重组KITL补充(四种剂量;N=5)对卵母细胞生长的影响。
- 培养第17或18天分离次级卵泡继续培养16天,评估卵母细胞成熟、受精和足月发育能力;处理后52-53天分娩后代。
主要发现
- AAV8、AAV9、AAVrh.10和AAVrh.32.33在野生型小鼠卵巢体外诱导的mCherry表达水平显著高于15种被评估血清型中的10种(P < 0.05)。
- AAV8-Kitl以剂量依赖方式促进KitlSl-t/KitlSl-t小鼠卵巢原始卵泡激活,1.0×10^11 vg/ml时获得最多次级卵泡(每个重建卵巢80个;P < 0.05)。
- AAV9-Kitl需要高2.5至10倍的滴度才能达到与AAV8-Kitl相当的次级卵泡形成水平;模拟处理的KitlSl-t/KitlSl-t小鼠卵巢未形成次级卵泡。
- 补充200 ng/ml重组KITL支持次级卵泡形成,水平与野生型小鼠卵巢相当;无论何种处理方法,超过10%的受精卵发育至足月。
- 47只后代基因组中未检出AAV DNA,所有受检雌鼠生育力正常。
临床怎么用
- 作者认为该研究建立了新型可控的体外平台,通过瞬时基因表达或因子补充补偿基因功能,无需永久性基因组修饰。
- 作者认为该方法为解析卵子发生中的基因功能、构建生殖障碍模型以及临床和保育场景中的生育力恢复策略提供了框架。
局限性
- 迄今为止,完全体外卵子发生仅在小鼠中实现,其对包括人类在内的其他物种的适用性尚未验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can in vitro systems, combined with transient gene expression or factor supplementation, completely restore fertility in congenitally infertile mice? SUMMARY ANSWER: Transient expression of Kitl via adeno-associated virus (AAV) vectors or supplementation with recombinant KITL in KitlSl-t/KitlSl-t mice-a model of congenital infertility caused by a mutation in the Kitl locus-resulted in the production of mature oocytes and the birth of healthy, fertile offspring. WHAT IS KNOWN ALREADY: Although in vivo gene delivery has enabled offspring production in infertile mouse models, low efficiency, unpredictability of parturition timing, inflammatory risk, possible viral genome integration, and lack of real-time oogenesis observation remain major concerns. Despite the potential of in vitro oogenesis as an alternative, complete functional restoration of gene deficiency has not been reported. STUDY DESIGN, SIZE, DURATION: AAV-mCherry was applied to wild-type mouse ovaries, and expression levels were compared across 15 serotypes (2.5 × 1011 viral genomes/ml; N = 4-12; 4-day infection, 20-day culture) to identify optimal AAV serotypes for ovarian gene delivery. The effects of AAV-Kitl infection (six doses; N = 3-5) and recombinant KITL supplementation (four doses; N = 5) on oocyte growth were evaluated in KitlSl-t/KitlSl-t mouse ovaries. On culture day 17 or 18, secondary follicles were isolated and cultured for an additional 16 days to evaluate oocyte competence for maturation, fertilization, and full-term development. Offspring were delivered 52-53 days after treatment initiation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovaries from KitlSl-t/KitlSl-t mice were dissociated into single cells and reaggregated in U-bottom wells with media containing AAV8-Kitl, AAV9-Kitl, or recombinant KITL. Reconstituted ovaries were cultured on insert membranes, thereby allowing primordial follicles to develop into secondary follicles. Isolated secondary follicles were further cultured to the antral stage, and cumulus-oocyte complexes were subjected to IVM and IVF. The resulting embryos were transferred to foster mothers. Finally, the offspring were subjected to PCR screening for AAV sequences and fertility tests. MAIN RESULTS AND THE ROLE OF CHANCE: AAV8, AAV9, AAVrh.10, and AAVrh.32.33 induced significantly higher levels of mCherry expression in wild-type mouse ovaries than 10 of the 15 AAV evaluated serotypes in vitro (P < 0.05). AAV8-Kitl promoted primordial follicle activation in a dose-dependent manner in KitlSl-t/KitlSl-t mouse ovaries, with the highest number of secondary follicles (80 per reconstituted ovary) obtained at 1.0 × 1011 vg/ml (P < 0.05). In contrast, AAV9-Kitl required 2.5- to 10-fold higher titers to achieve comparable levels of secondary follicle formation. Contrastingly, no secondary follicles were formed in KitlSl-t/KitlSl-t mouse ovaries following mock treatment. Furthermore, supplementation with 200 ng/ml recombinant KITL supported secondary follicle formation at levels comparable to those in the wild-type mouse ovaries. More than 10% of fertilized oocytes developed to full term, regardless of the treatment method. AAV DNA was not detected in the genomes of the 47 offspring, and all tested female mice exhibited normal fertility. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: To date, complete in vitro oogenesis has only been achieved in mice; its applicability to other species, including humans, remains unverified. WIDER IMPLICATIONS OF THE FINDINGS: This study establishes a novel and controllable in vitro platform to compensate for gene function through transient gene expression or factor supplementation, without permanent genomic modification. This approach provides a powerful framework for the dissection of gene functions during oogenesis, modeling of reproductive disorders, and development of fertility restoration strategies in both clinical and conservation contexts. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by KAKENHI (grant numbers 18H05547, 23K27088, and 25H01353). The authors declare no competing interests.
引用
- Yoshida K, Kimura S, Taguchi M, et al. In vitro system completely restores oogenesis in congenitally infertile mice. Hum Reprod. 2025. PMID: 41057044. doi:10.1093/humrep/deaf194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。